Inhibikase Therapeutics Q3 2023 Earnings Report $2.81 +0.09 (+3.31%) As of 01/21/2025 04:00 PM Eastern Earnings HistoryForecast Inhibikase Therapeutics EPS ResultsActual EPS-$0.86Consensus EPS -$1.12Beat/MissBeat by +$0.26One Year Ago EPSN/AInhibikase Therapeutics Revenue ResultsActual Revenue$0.08 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInhibikase Therapeutics Announcement DetailsQuarterQ3 2023Date11/14/2023TimeN/AConference Call ResourcesIKT Earnings History Inhibikase Therapeutics Earnings HeadlinesBullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of StockJanuary 21 at 8:40 AM | finance.yahoo.comInhibikase Therapeutics files to sell 58.31M shares of common stock for holdersNovember 19, 2024 | markets.businessinsider.comPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader in the country – in the next 30 days. In fact, I believe it could begin as soon as January 29th… Meaning you don’t have much time to prepare.January 22, 2025 | Timothy Sykes (Ad)Inhibikase: Potential To Improve Current Treatment Options For PAH PatientsNovember 19, 2024 | seekingalpha.comInhibikase Therapeutics’ Promising Developments and Financial Backing Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comInhibikase Therapeutics: Strategic Developments and Financial Position Underpin Buy RatingNovember 15, 2024 | markets.businessinsider.comSee More Inhibikase Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibikase Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibikase Therapeutics and other key companies, straight to your email. Email Address About Inhibikase TherapeuticsInhibikase Therapeutics (NYSE:IKT), a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.View Inhibikase Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings CSX (1/23/2025)Intel (1/23/2025)Texas Instruments (1/23/2025)Freeport-McMoRan (1/23/2025)General Electric (1/23/2025)Union Pacific (1/23/2025)Elevance Health (1/23/2025)Verizon Communications (1/24/2025)NextEra Energy (1/24/2025)American Express (1/24/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
